Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of BMN 044 in Duchenne Muscular Dystrophy
NCT02958202Phase 2Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2016
- Primary completion
- Sep 2016
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 4
01
Overview
Phase 2, open-label trial of PRO044 in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by BioMarin Pharmaceutical. Primary endpoint: Number of subjects with 1 or more treatment emergent adverse events following BMN044 dosing. Started Apr 2016; status: terminated.
02
Drugs
PRO044
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02958202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958202.